Two missense mutations in the CD44 gene encode two new antigens of the Indian blood group system
Correction(s) for this article
-
CORRECTION
- Volume 47Issue 9Transfusion
- pages: 1741-1741
- First Published online: August 20, 2007
Joyce Poole
From the Bristol Institute for Transfusion Sciences and International Blood Reference Laboratory, National Blood Service, Bristol, UK; Sanquin Blood Supply, Diagnostic Services, Amsterdam, the Netherlands; Charité, Institut für Transusionsmedizin, Berlin, Germany; and the National Blood Service, Leeds Centre, Leeds, UK.
Search for more papers by this authorLouise Tilley
From the Bristol Institute for Transfusion Sciences and International Blood Reference Laboratory, National Blood Service, Bristol, UK; Sanquin Blood Supply, Diagnostic Services, Amsterdam, the Netherlands; Charité, Institut für Transusionsmedizin, Berlin, Germany; and the National Blood Service, Leeds Centre, Leeds, UK.
Search for more papers by this authorNicole Warke
From the Bristol Institute for Transfusion Sciences and International Blood Reference Laboratory, National Blood Service, Bristol, UK; Sanquin Blood Supply, Diagnostic Services, Amsterdam, the Netherlands; Charité, Institut für Transusionsmedizin, Berlin, Germany; and the National Blood Service, Leeds Centre, Leeds, UK.
Search for more papers by this authorFrances A. Spring
From the Bristol Institute for Transfusion Sciences and International Blood Reference Laboratory, National Blood Service, Bristol, UK; Sanquin Blood Supply, Diagnostic Services, Amsterdam, the Netherlands; Charité, Institut für Transusionsmedizin, Berlin, Germany; and the National Blood Service, Leeds Centre, Leeds, UK.
Search for more papers by this authorMarijke A.M. Overbeeke
From the Bristol Institute for Transfusion Sciences and International Blood Reference Laboratory, National Blood Service, Bristol, UK; Sanquin Blood Supply, Diagnostic Services, Amsterdam, the Netherlands; Charité, Institut für Transusionsmedizin, Berlin, Germany; and the National Blood Service, Leeds Centre, Leeds, UK.
Search for more papers by this authorJosé A.C.M. Van Der Mark-Zoet
From the Bristol Institute for Transfusion Sciences and International Blood Reference Laboratory, National Blood Service, Bristol, UK; Sanquin Blood Supply, Diagnostic Services, Amsterdam, the Netherlands; Charité, Institut für Transusionsmedizin, Berlin, Germany; and the National Blood Service, Leeds Centre, Leeds, UK.
Search for more papers by this authorNorbert Ahrens
From the Bristol Institute for Transfusion Sciences and International Blood Reference Laboratory, National Blood Service, Bristol, UK; Sanquin Blood Supply, Diagnostic Services, Amsterdam, the Netherlands; Charité, Institut für Transusionsmedizin, Berlin, Germany; and the National Blood Service, Leeds Centre, Leeds, UK.
Search for more papers by this authorDiane Armstrong
From the Bristol Institute for Transfusion Sciences and International Blood Reference Laboratory, National Blood Service, Bristol, UK; Sanquin Blood Supply, Diagnostic Services, Amsterdam, the Netherlands; Charité, Institut für Transusionsmedizin, Berlin, Germany; and the National Blood Service, Leeds Centre, Leeds, UK.
Search for more papers by this authorMark Williams
From the Bristol Institute for Transfusion Sciences and International Blood Reference Laboratory, National Blood Service, Bristol, UK; Sanquin Blood Supply, Diagnostic Services, Amsterdam, the Netherlands; Charité, Institut für Transusionsmedizin, Berlin, Germany; and the National Blood Service, Leeds Centre, Leeds, UK.
Search for more papers by this authorGeoff Daniels
From the Bristol Institute for Transfusion Sciences and International Blood Reference Laboratory, National Blood Service, Bristol, UK; Sanquin Blood Supply, Diagnostic Services, Amsterdam, the Netherlands; Charité, Institut für Transusionsmedizin, Berlin, Germany; and the National Blood Service, Leeds Centre, Leeds, UK.
Search for more papers by this authorJoyce Poole
From the Bristol Institute for Transfusion Sciences and International Blood Reference Laboratory, National Blood Service, Bristol, UK; Sanquin Blood Supply, Diagnostic Services, Amsterdam, the Netherlands; Charité, Institut für Transusionsmedizin, Berlin, Germany; and the National Blood Service, Leeds Centre, Leeds, UK.
Search for more papers by this authorLouise Tilley
From the Bristol Institute for Transfusion Sciences and International Blood Reference Laboratory, National Blood Service, Bristol, UK; Sanquin Blood Supply, Diagnostic Services, Amsterdam, the Netherlands; Charité, Institut für Transusionsmedizin, Berlin, Germany; and the National Blood Service, Leeds Centre, Leeds, UK.
Search for more papers by this authorNicole Warke
From the Bristol Institute for Transfusion Sciences and International Blood Reference Laboratory, National Blood Service, Bristol, UK; Sanquin Blood Supply, Diagnostic Services, Amsterdam, the Netherlands; Charité, Institut für Transusionsmedizin, Berlin, Germany; and the National Blood Service, Leeds Centre, Leeds, UK.
Search for more papers by this authorFrances A. Spring
From the Bristol Institute for Transfusion Sciences and International Blood Reference Laboratory, National Blood Service, Bristol, UK; Sanquin Blood Supply, Diagnostic Services, Amsterdam, the Netherlands; Charité, Institut für Transusionsmedizin, Berlin, Germany; and the National Blood Service, Leeds Centre, Leeds, UK.
Search for more papers by this authorMarijke A.M. Overbeeke
From the Bristol Institute for Transfusion Sciences and International Blood Reference Laboratory, National Blood Service, Bristol, UK; Sanquin Blood Supply, Diagnostic Services, Amsterdam, the Netherlands; Charité, Institut für Transusionsmedizin, Berlin, Germany; and the National Blood Service, Leeds Centre, Leeds, UK.
Search for more papers by this authorJosé A.C.M. Van Der Mark-Zoet
From the Bristol Institute for Transfusion Sciences and International Blood Reference Laboratory, National Blood Service, Bristol, UK; Sanquin Blood Supply, Diagnostic Services, Amsterdam, the Netherlands; Charité, Institut für Transusionsmedizin, Berlin, Germany; and the National Blood Service, Leeds Centre, Leeds, UK.
Search for more papers by this authorNorbert Ahrens
From the Bristol Institute for Transfusion Sciences and International Blood Reference Laboratory, National Blood Service, Bristol, UK; Sanquin Blood Supply, Diagnostic Services, Amsterdam, the Netherlands; Charité, Institut für Transusionsmedizin, Berlin, Germany; and the National Blood Service, Leeds Centre, Leeds, UK.
Search for more papers by this authorDiane Armstrong
From the Bristol Institute for Transfusion Sciences and International Blood Reference Laboratory, National Blood Service, Bristol, UK; Sanquin Blood Supply, Diagnostic Services, Amsterdam, the Netherlands; Charité, Institut für Transusionsmedizin, Berlin, Germany; and the National Blood Service, Leeds Centre, Leeds, UK.
Search for more papers by this authorMark Williams
From the Bristol Institute for Transfusion Sciences and International Blood Reference Laboratory, National Blood Service, Bristol, UK; Sanquin Blood Supply, Diagnostic Services, Amsterdam, the Netherlands; Charité, Institut für Transusionsmedizin, Berlin, Germany; and the National Blood Service, Leeds Centre, Leeds, UK.
Search for more papers by this authorGeoff Daniels
From the Bristol Institute for Transfusion Sciences and International Blood Reference Laboratory, National Blood Service, Bristol, UK; Sanquin Blood Supply, Diagnostic Services, Amsterdam, the Netherlands; Charité, Institut für Transusionsmedizin, Berlin, Germany; and the National Blood Service, Leeds Centre, Leeds, UK.
Search for more papers by this authorAbstract
BACKGROUND: Blood samples were referred over a 10-year period from five patients whose serum samples contained antibodies to unidentified high-incidence antigens. Three patients (A, B, C) were of Moroccan origin and their antibodies and red blood cells (RBCs) were mutually compatible, but incompatible with those of the other two patients (D, E), who were of Pakistani origin. The antibodies and RBCs of D and E were mutually compatible, but incompatible with those of Patients A, B, and C. All the antibodies were detected during pregnancy.
STUDY DESIGN AND METHODS: Serologic tests, including the use of enzyme-treated and chemically modified RBCs, suggested a relationship to CD44 (Indian blood group system). The monoclonal antibody immobilization of erythrocyte antigens (MAIEA) assay with monoclonal CD44 antibodies, immunoblotting of RBC membranes, and CD44 gene sequencing were carried out.
RESULTS: Positive reactions in the MAIEA assay confirmed that the patients' antibodies are directed at CD44. Immunoblotting with two of the antibodies gave positive reactions of identical size to monoclonal anti-CD44 and failed to react with the RBCs of a CD44-deficient patient. One of the antibodies reacted with purified CD44. Sequencing of Exons 1 to 5 of CD44 revealed 255C>G in Exon 3 for A, B, and C encoding H85Q and 488C>A in Exon 5 for D and E encoding T163R.
CONCLUSION: Two novel CD44 antigens of high incidence have been identified: IN3 (INFI) and IN4 (INJA) in the IN (Indian) blood group system. Lack of IN3 and IN4 results from homozygosity for mutations encoding H85Q and T163R in CD44, respectively.
REFERENCES
- 1 Lesley J, Hyman R, Kincade PW. CD44 and its interaction with extracellular matrix. Adv Immunol 1993; 54: 271-335.
- 2 Day AJ, Prestwich GD. Hyaluronan-binding proteins: tying up the giant. J Biol Chem 2002; 277: 4585-8.
- 3 Telen MJ. Erythrocyte adhesion receptors: blood group antigens and related molecules. Transfus Med Rev 2005; 19: 32-44.
- 4 Screaton GR, Bell MV, Jackson DG, et al. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci U S A 1992; 89: 12160-4.
- 5 Tölg C, Hofmann M, Herrlich P, Ponta H. Splicing choice from ten variant exons establishes CD44 variability. Nucleic Acid Res 1993; 21: 1225-9.
- 6 Stamenkovic I, Amiot M, Pesando JM, Seed B. A lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family. Cell 1989; 56: 1057-62.
- 7 Goldstein LA, Zhou DFH, Picker LJ, et al. A human lymphocyte homing receptor, the Hermes antigen, is related to cartilage proteoglycan core and link proteins. Cell 1989; 56: 1063-72.
- 8 Harn HJ, Isola N, Cooper DL. The multispecific cell adhesion molecule CD44 is represented in reticulocyte cDNA. Biochem Biophys Res Comm 1991; 178: 1127-34.
- 9
Daniels G.
Human blood groups. 2nd ed.
Oxford: Blackwell Science; 2002.
10.1002/9780470987018 Google Scholar
- 10 Spring FA, Dalchau R, Daniels GL, et al. The Ina and Inb blood group antigens are located on a glycoprotein of 80,000 MW (the CDw44 glycoprotein) whose expression is influenced by the In(Lu) gene. Immunology 1988; 64: 37-43.
- 11 Telen MJ, Udani M, Washington MK, et al. A blood group-related polymorphism of CD44 abolishes a hyalouronan-binding consensus sequence without preventing hyalouronan binding. J Biol Chem 1996; 271: 7147-53.
- 12 Rao N, Udani M, Telen MJ. Demonstration by monoclonal antibody immobilisation of erythrocyte antigens and dot blot analysis that both the In and AnWj blood group antigens reside on CD44 [abstract]. Transfusion 1994; 34: 25S.
- 13 Telen MJ, Rao N, Udani M, Liao HX, Haynes BF. Relationship of the AnWj antigen to expression of CD44 [abstract]. Transfusion 1993; 33: 48S.
- 14 Marsh WL. Scoring of hemagglutination reactions. Transfusion 1972; 12: 352-3.
- 15 Daniels G. Effect of enzymes on and chemical modifications of high-frequency red cell antigens. Immunohematology 1992; 8: 53-7.
- 16 Petty AC. Monoclonal antibody-specific immobilistaion of erythrocye antigens (MAIEA): a new technique to selectively determine antigenic sites on red cell membranes. J Immunol Methods 1993; 161: 91-5.
- 17 Anstee DJ, Gardner B, Spring FA, et al. New monoclonal antibodies in CD44 and CD58: their use to quantify CD44 and CD58 on normal human erythrocytes and to compare the distribution of CD44 and CD58 in human tissues. Immunology 1991; 74: 197-205.
- 18 Smythe JS, Spring FA, Gardner B, et al. Monoclonal antibodies recognizing epitopes on the extracellular face and intracellular N-terminus of the human erythrocyte anion transporter (band 3) and their application to the analysis of South East Asian ovalocytes. Blood 1995; 85: 2929-36.
- 19 Parsons SF, Jones J, Anstee DJ, et al. A novel form of congenital dyserythropoietic anemia associated with deficiency of erythroid CD44 and a unique blood group phenotype [In (a–b–) Co (a–b–) ]. Blood 1994; 83: 860-8.
- 20 Mallinson G, Martin PG, Anstee DJ, et al. Identification and partial characterization of the human erythrocyte membrane component(s) that express the antigens of the LW blood-group system. Biochem J 1986; 234: 649-52.
- 21 Daniels G, Flegel WA, Fletcher A, et al. International Society of Blood Transfusion Committee on Terminology for Red Cell Surface Antigens. Cape Town report. Vox Sang 2007; 92: 250-3.
- 22 Joshi SR. Immediate haemolytic transfusion reaction due to anti-Inb. Vox Sang 1992; 63: 232-3.
- 23 Bhatia HM, Badakere SS, Mokashi SA, Parab BB. Studies on the blood group antigen Ina. Immunol Commun 1980; 9: 203-15.
- 24 Ferguson DJ, Gaal HD. Some observations on the Inb antigen and evidence that anti-Inb causes accelerated destruction of radiolabeled red cells. Transfusion 1988; 28: 479-82.
- 25 Garner SF, Devenish A. Do monocyte ADCC assays accurately predict the severity of hemolytic disease of the newborn caused by antibodies to high-frequency antigens? Immunohematology 1996; 12: 20-6.
- 26 Badakere SS, Vasantha K, Bhatia HM, et al. High frequency of Ina antigen among Iranians and Arabs. Hum Hered 1980; 30: 262-3.
- 27 Poole J, Levene C, Bennett M, et al. A family showing inheritance of the Anton blood group antigen AnWj and independence of AnWj from Lutheran. Transfus Med 1991; 1: 245-51.
- 28 Chan JY, Watt SM. Adhesion receptors on haematopoietic progenitor cells. Br J Haematol 2001; 112: 541-57.
- 29 Bajorath J, Greenfield B, Munro SB, Day AJ, Aruffo A. Identification of CD44 residues important for hyaluronan binding and delineation of the binding site. J Biol Chem 1998; 273: 338-43.
- 30 Teriete P, Banerji S, Noble M, et al. Structure of the regulatory hyaluronan binding domain in the inflammatory leukocyte homing receptor CD44. Mol Cell 2004; 13: 483-96.
- 31 Takeda M, Ogino S, Umemoto R, et al. Ligand-induced structural changes of the CD44 hyaluronan-binding domain revealed by NMR. J Biol Chem 2006; 281: 40089-95.
Citing Literature
